NCT00178841View on ClinicalTrials.gov

Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL

PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions
Cutaneous T-cell LymphomaMycosis FungoidesSezary Syndrome
Interventions
DRUG

Rosiglitazone and Bexarotene

rosiglitazone added to bexarotene capsules

Trial Locations (1)

37232-5227

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
lead

Vanderbilt University

OTHER

NCT00178841 - Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL | Biotech Hunter | Biotech Hunter